Bacterial vaginosis is a common condition among women of reproductive age and is 16 associated with potentially serious side-effects, including an increased risk of preterm birth. 17
Introduction 35
Bacterial vaginosis (BV) is widely considered to be the most common vaginal disorder 36 among women of reproductive age (1) . In a sample of self-collected vaginal swabs from 3,700 37 women, the prevalence of BV was estimated at 29% in the general population of women aged 38 14-49 years and 50% in African-American women (2). Typically, affected patients present with 39 inflammation of the vagina that can result in discharge, itching, and pain. That said, clinical 40 presentation can vary considerably, with asymptomatic infections being noted with great 41 regularity (2). A wide variety of risk factors for BV have been noted, including sexual activity 42 (3, 4) , the presence of other sexually transmitted infections (5), as well as race and ethnicity (2). 43 Important complications of BV infection include an increased risk of preterm delivery in 44 pregnant women (6) and of HIV acquisition and transmission (7) . In some women, clearance of 45 the infection, even with standard of care, is difficult to achieve, often resulting in chronic or 46 recurrent symptoms (8). 47 Improved strategies for detecting BV infection have been the subject of much discussion, 48 due to the reduction in the quality of life that can result from an active infection and the 49 reasonably high prevalence of BV in women (9). Recent advances in technology have driven 50 interest in DNA-based, quantitative, diagnostic algorithms that are theoretically quicker to 51 perform than culture, more accurate in their results, and are potential candidates as point-of-care 52 devices. However, the seemingly complex biology and dynamics of BV infection, along with 53 important limitations in "gold-standard" approaches, have complicated these efforts. 54
One confounding factor is the consistent observation that BV is associated not with a 55 single causative pathogen, but rather with a broad disruptive shift in the microbial population: 56 from a healthy Lactobacilli-dominated environment to one largely overtaken by organisms such 57
as Gardnerella, various mycoplasma, and a heterogeneous collection of facultative anaerobes 58 (10) . With this shift come changes in the underlying interactions among different organisms, 59 changes in the metabolites produced by the local bacterial community, and changes to the host's 60 immune response. Together, these factors produce key signs and symptoms of infection. This 61 dynamic mechanism of disease manifestation results in a condition with all the standard 62 hallmarks of a complex etiology. For example, BV presents clinically in numerous ways, and 63 individual symptoms can be the result of multiple systematic shifts in the vaginal microbiome in 64 favor of a variety of pathogenic organisms. Sometimes women experience no clinical 65 symptoms; in fact, a significant percentage of affected patients are asymptomatic (11, 33) . This 66 statistic is particularly important in the context of pregnancy, where it has been shown that BV 67 infection, whether symptomatic or not, is associated with preterm birth (6). 68
In addition, the vaginal microbiota has recently been shown to be longitudinally dynamic 69 in healthy individuals; that is, changes are seen to occur in near-real time over days and weeks 70 (12). The impact of microbial population flux on the maintenance of bacterial community 71 homeostasis, on the resolution of symptoms post-infection, and on the repression of symptoms in 72 asymptomatic women is not well understood. Nevertheless, an oft-changing microbiota poses 73 difficulties for accurate diagnosis, since efficient molecular testing depends on samples taken at a 74 singular point in time. 75
Given the complexity of the dynamics that lead to clinical presentation, it is unsurprising 76 that diagnosis of BV infections has historically been a challenge. While Gram staining plus 77 Nugent scoring (13) is considered the gold-standard, it is a technique fraught with problems: 1. 78
Nugent requires expertise at staining and scoring morphotypes; 2. several clinically significant 79 microbes, either of variable morphology or lacking a cell wall, are regularly misidentified or 80 overlooked (9); and 3. some 20% of symptomatic subjects score between 4 and 6, rendering 81 their status "intermediate"-an ambiguous diagnosis that is not helpful for the healthcare 82 provider (14) and may lead to inappropriate clinical intervention, or, conversely, to no 83 intervention when it is actually needed. Given the complexity of microbiome alterations now 84 known to be associated with disease, the second of these shortcomings may account for Nugent's 85 reportedly poor sensitivity and specificity (13). Finally, Nugent scoring has also been shown to 86 occasionally miss differential diagnoses such as Trichomonas vaginalis infections (15) with 87 potentially problematic effects on patient well-being due to inappropriate therapy. 88
An older and more commonly used diagnostic tool is the application of Amsel's criteria. 89 This test, first described in 1983, requires the satisfaction of at least three of four criteria to 90 qualify for a BV diagnosis: elevated pH (>4.5), characteristic discharge, fishy odor upon the 91 addition of 10% KOH to a slide prep, and the microscopic visualization of "clue cells" (smaller 92 bacteria adhering to epithelial cells) in a wet mount (16). However, while easy to implement in 93 theory, Amsel's criteria are reportedly underutilized in clinical settings (17) and are technically 94 limited by the lack of consideration of the abundance of healthy Lactobacillus species (18). 95
These and other acknowledged failings of the gold-standard diagnostic techniques for BV 96 have recently fueled a search for alternatives leveraging new technology. Today, there are a 97 variety of alternatives in the marketplace that claim ease of testing, enhanced sensitivity and 98 specificity, as well as reduced cost. Relatively few of these can be used at the point-of care 99 (PoC) (19,20); rather, most available tests require sending a sample -often in the form of a 100 vaginal swab -to a laboratory for testing. Though not as expedient as a PoC diagnostic, at 1 to 2 101 days for a result after sample transport and testing, versus minutes to hours for a PoC result, the 102 referencing of samples to an external laboratory offers several key advantages. Most notably, 103 some clinical laboratories can simultaneously screen samples for a broad range of microbial 104 targets covering multiple conditions, not merely BV. The ability to offer a differential diagnosis 105 is a key advantage for symptomatic patients, since infections other than BV can present with 106 very similar signs and symptoms. Many labs can also generate bacteria-specific 107 presence/absence or semi-quantitative information, while also detecting difficult-to-culture, 108 anaerobic, and commensal microorganisms. Such data offer the potential for healthcare 109 providers, who are often faced with interpreting ambiguous signs and symptoms, to receive 110 greater diagnostic clarity. Similarly, they can be alerted to mixed/co-infections, a situation 111 reported to affect 20% of BV+ patients (21). Finally, providers can potentially receive specific 112 recommendations for therapy (e.g. antibiotic regimens or combinations of treatment options 113 specific to the pathogen(s) detected). While in no way a replacement for a thorough physical 114 examination and detailed capture of patient history (22), such molecular-based screening holds 115 great promise for the enhancement of the current standard-of-care. 116
Here we present the refinement and performance evaluation of an existing quantitative 117 molecular diagnostic for BV that eliminates the challenges demonstrated by Amsel and Nugent 118 tests, while also providing an accurate diagnosis via genus and species-specific information for 119 both pathogenic and non-pathogenic bacteria. The test, based on real-time PCR, is offered in a 120 highly customizable format, allowing individual laboratories to add or subtract content as future 121 needs and research developments dictate. The approach also permits simultaneous screening of 122 an assortment of other vaginal pathogens with no additional labor or consumable requirements, 123 thereby enabling differential diagnoses -an added value of this test over current PoC solutions. for BV (1, 9, 14, 25, 26, 27) , and expert reviews of both of these subjects (28,29,30,31,32). We 132 found that numerous studies have shown that the amounts of particular bacteria -and not merely 133 their presence or absence -play a role in the development and/or persistence of BV 134 (1, 9, 14, 17, 27, 28, 31, 34, 35) . Ultimately, fourteen BV-associated microorganisms (TABLE 1) that 135 would theoretically maximize diagnostic specificity while remaining cost-effective to the clinical 136 laboratory were selected for inclusion in the new diagnostic test. TaqMan®-based assays were 137 designed with the assistance of ThermoFisher's bioinformatic pipeline to detect bacterial-specific 138 genes down to the species level, reported to be present at one copy per microbe, a fact important 139 for the relative abundance calculation of each microbial target. The assays were subsequently 140 spotted into the through-holes of a custom-designed TaqMan OpenArray plate for vaginal 141 microbiota investigations (available from ThermoFisher Scientific). 142
Since bacterial vaginosis, candidiasis, and trichomoniasis are all indicated in vaginitis, 143 present clinically with similar signs and symptoms, and are often observed in co-infected 144 patients, assays specific to these infections were added to the panel as an aid to differential 145 diagnoses. Furthermore, because Candida albicans infections are treated differently than non-146 albicans infections, five specific yeast species were also included in the final panel design. 147
Algorithm Development and Study Population 148
During the original algorithm design phase, several statistical and algorithmic approaches 149 were applied to a sample of patients (410 antibiotic-naïve, including 25 asymptomatic women 150 showing no clue cells on analysis for Amsel's criteria) and evaluated with respect to sensitivity 151 and specificity. These included a number of multivariate linear and mixed models as well as a 152 variety of other techniques. In general, linear regression techniques performed poorly with 153 respect to sensitivity (i.e., the ability to identify BV+ individuals), but performed fairly well with 154 respect to specificity (i.e., the ability to exclude BV as a diagnosis). Alternative strategies, such 155 as those that produced the final CLS1 algorithm, showed improved overall performance 156 (especially increased sensitivity), albeit with slightly reduced specificity. Ultimately, the highest 157 performing quantitative model using measures of relative abundance was chosen for validation, 158 as opposed to one based solely on presence/absence data. unclear guidelines for treatment. Interestingly, via the mutually reinforcing patterns described 243 above, CLS2.0q appears to provide clear resolution for such patients (Fig. 1b) Assays for candidiasis, trichomoniasis, and five specific Candida species were included 251 in the final panel design to enable differential diagnosis for these infections due to their clinically 252 similar presentations (TABLE 2) As such, improved strategies for detecting BV infection have been a subject of much 267 discussion. Recent advances in sequencing technologies, the very same that have begun 268 revealing the biology responsible for disease, also show great promise for improving diagnosis. However, these methods utilize presence/absence determinations for some diagnostic features 282 and for others provide merely a semi-quantitative categorization of patients. These limitations 283 result in poor resolution by the gold-standard approach. Specifically, Nugent scoring provides a 284 somewhat-ambiguous finding of "Low," "Intermediate," or "High" rather than a more concrete 285 diagnosis of "BV+" or "BV-." 286
The diagnostic method we validate here appears to much more accurately capture the 287 complex biology of BV compared to existing alternatives. It identifies a clear reinforcing pattern 288 of abundance (see Fig. 1a ) of multiple pathogenic and commensal Lactobacilli species that 289 provides a clear and accurate diagnosis, even in diagnostically ambiguous "Intermediate" 290 patients (Fig. 1b) . The method also provides improved sensitivity and specificity over current 291 standard-of-care diagnostic tools. Interestingly, these metrics likely underestimate the number of 292 true positive and true negative individuals, since the algorithm was necessarily compared to a 293 standard with known flaws. It is possible that these flaws produce an upper limit on performance 294 that is unrelated to the clear signal produced by CLS2.0q. The actual sensitivity and specificity 295 of the CLS2.0q diagnostic algorithm may therefore be greater than reported. 296
In addition to providing clarity for the ambiguous Nugent "Intermediate" subjects, 297 CLS2.0q also appears to perform well in asymptomatic patients. This is especially valuable as it 298 is well documented that a majority of BV cases present with no clinical symptoms at all. 299
Interestingly, most of the asymptomatic patients involved in the validation were diagnosable by 300 CLS2.0q as BV+ (FIG 1c) . Again, via clearly interpretable biological pattern recognition, 301
CLS2.0q appears to aid in the accurate diagnosis of such patients as well, though additional 302 studies focused on this subgroup would be necessary to confirm this observation. 303
In addition to the improved capture of biologically-consistent, patient-specific patterns of 304 dysregulation in the vaginal microbiome, CLS2.0q also incorporates several technical 305 improvements over existing methods. For example, together with the detection technology, it is 306 capable of identifying both rare and difficult-to-culture organisms that are currently missed by 307 standard diagnosis methods. Additionally, OpenArray technology provides several key 308 advantages over previous approaches. These include increased flexibility of microbial target choices, improved accuracy of microbial identification, and high-throughput capability. They 310 also allow for the refinement of platform content as future research continues to reveal the 311 underlying dynamics of infection. 312
This successful validation of the CLS2.0q algorithm was nonetheless limited in several 313 ways. The first is the somewhat small overall sample size in the validation set of 172 women. 314
However, though the validation dataset may seem limited, the original training set included 410 315 symptomatic and asymptomatic women, and all findings during the original algorithm 316 development were very similar to those presented here (data not shown). The second limitation 317 is this study's somewhat biased sample of patients. Whereas the majority of subjects in this 318 dataset self-identify as Latina, the ideal validation would have included representative samples of 319 all ethnicities in order to fully control for known and potential differences amongst groups. An 320 ideal study would also have fully controlled for geography and socio-economic status. However, 321 the availability of subjects and other logistical challenges limited collection to a single 322 location/health system whose population may not be fully representative at the national level. 323
Another limitation is inherent to the biology of the condition itself, namely the dynamics 324 of the vaginal microbiome in real-time that inevitably introduces variation due to the status of the 325 dysregulation at the time of sampling. While formally unaccounted for in our analyses, the 326 robustness of the algorithm displayed in development and in this validation strongly suggest that 327 we have sampled over a sufficient number of dysregulated states to reflect the majority of the 328 relevant biological variation detectable by the method. 329
Ultimately, this validation established CLS2.0q as a quantitative, sensitive, specific, 330 accurate, and robust algorithm for the diagnosis of bacterial vaginosis. It is demonstrably 331 superior to gold-standard approaches at identifying the underlying biological dynamics of 332 dysregulation in the vaginal microbiome that underlie the condition. It enables efficient 333 differential diagnosis of multiple other conditions that present in a clinically similar manner. 334
Finally, future work may allow the algorithm to be extended to the data-driven recommendation 335 of personalized treatment regimes, including those that may help circumvent and/or avoid 336 antibiotic resistance. Ongoing research is expected to identify additional organisms of interest 337 for bacterial vaginosis, and CLS2.0q is well positioned to rapidly include this information in 338 future refinements of the algorithm. 339
It is evident that quantitative methods of diagnosis provide key improvements over 340 current approaches to the diagnosis and treatment of complex infections. It is hoped that the 341 technology employed here will enable point-of-care compatible turnaround times and broaden 342 the impact of these techniques in personalized medicine. In addition to flexibility and efficiency, 343 there is also the potential for these approaches to identify drug-resistant organisms, and thus to 344 suggest specific and personalized treatment regimens for individual patients. Furthermore, these 345 techniques can be used to test for and diagnose other conditions, such as respiratory infections, 346 gastrointestinal dysregulation, and wound healing concerns. 347 348
